| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.01 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.01 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.02 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.02 |